Posso obtê-lo?
Sim, se um médico decidir que é adequado para si. Victoza está autorizado na UE e pode ser prescrito após uma avaliação médica.
VictozaApenas com receita
Consulta médica online para Victoza.
Um médico licenciado na UE analisa o seu caso e, se for elegível, emite uma receita eletrónica válida em qualquer farmácia da UE ao abrigo da Diretiva 2011/24/UE.
- Daily pen with flexible titration
- One of the longest-standing GLP-1s in Europe
- An option when a weekly GLP-1 isn't the right fit
Iniciar consultaIniciar consulta · 25 €/mês
Reembolso total se uma avaliação não for aprovada · A medicação, se for prescrita, é dispensada e paga separadamente numa farmácia.
EM TERMOS SIMPLES
O que é Victoza e como obter tratamento
A liraglutida é um medicamento administrado através de uma injeção sob a pele uma vez por dia. Tal como a semaglutida, imita a hormona intestinal natural GLP-1, que avisa o cérebro de que já comeu o suficiente, reduzindo assim a fome e o desejo de comer. Para o controlo do peso na UE, é vendida como Saxenda e utilizada em conjunto com uma alimentação com menos calorias e mais atividade física. Está autorizada na UE para o controlo do peso desde março de 2015.
Victoza está autorizado para utilização na UE desde 23 de março de 2015. Por isso, um médico habilitado pode prescrevê-lo quando for clinicamente adequado para si.
Saiba mais sobre péptidos em Peptidepedia.
O que posso tomar em alternativa?
Os nossos médicos avaliam todas as opções de Perda de peso e recomendam a que melhor se adapta ao seu historial clínico e aos seus objetivos.
Veja todas as opções de Perda de pesoO que mostram os estudos?
Todos os ensaios sobre Victoza estão indicados abaixo, com o respetivo número de registo, o número de participantes e a indicação de que os resultados foram revistos por pares ou de que são apenas um anúncio da empresa.
Ir para os estudosEVIDÊNCIA VERIFICADA
Victoza: guia de evidência e regulamentação.
O QUE É
Como atua
It copies the gut hormone GLP-1, which increases the feeling of fullness and reduces hunger and food cravings.
- GLP-1
FASE DE DESENVOLVIMENTO
Medicamento autorizado na UE
Registo de ensaios1 ensaios registados
Cada identificador NCT liga ao registo ClinicalTrials.gov. Um resultado comunicado não equivale a uma publicação revista por pares.
| ENSAIO / NCT | POPULAÇÃO | PARTICIPANTES | ESTADO | RESULTADO / CONCLUSÃO |
|---|---|---|---|---|
| SCALE Obesity and Prediabetes (NN8022-1839)NCT01272219 | Adults with a BMI of 30 kg/m² or more, or 27 kg/m² or more with treated high blood pressure or abnormal blood fats, without type 2 diabetes; all received lifestyle counselling | 3,731 | Com resultados | 2015-07-02 |
O que os estudos comunicaram
Os resultados estão separados por fonte e grau de evidência para não confundir dados científicos com anúncios do fabricante.
Revisto por pares
Pi-Sunyer X, Astrup A, Fujioka K, et al; SCALE Obesity and Prediabetes NN8022-1839 Study Group. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. doi:10.1056/NEJMoa1411892 (PMID 26132939)| DOSE OU GRUPO | ALTERAÇÃO MÉDIA DO PESO | SEMANAS |
|---|---|---|
| 3.0 mg once daily | −8.0% | 56 |
| Placebo | −2.6% | 56 |
Everyone in the trial also received lifestyle counselling, people with type 2 diabetes were excluded, and the primary result covers 56 weeks only.
SINAIS DE SEGURANÇA IDENTIFICADOS
O que foi comunicado com Victoza.
Nausea
Reported by 40.2% of people on liraglutide 3.0 mg versus 14.7% on placebo in the SCALE Obesity and Prediabetes trial.
Diarrhoea
Reported by 20.9% on liraglutide 3.0 mg versus 9.3% on placebo in the same trial.
Constipation
Reported by 20.0% on liraglutide 3.0 mg versus 8.7% on placebo in the same trial.
Vomiting
Reported by 16.3% on liraglutide 3.0 mg versus 4.1% on placebo in the same trial.
Gallstone problems
Acute gallstone events were reported by 2.3% on liraglutide 3.0 mg versus 0.9% on placebo across the EMA weight-management trial pool, mainly gallstones (1.5% versus 0.5%).
Acute pancreatitis
Independently confirmed in 7 people (0.2%) on liraglutide 3.0 mg versus 1 person (under 0.1%) on placebo across the EMA weight-management trial pool.
Serious side effects overall
Serious adverse events were reported in 6.2% of the liraglutide group versus 5.0% of the placebo group in the SCALE Obesity and Prediabetes trial.
25 €/mês (cobrado 25 € a cada 28 dias)Iniciar consulta médica
FormaCaneta pré-cheia
FrequênciaUma vez por dia
ResultadosGradual, week by week
O que paga à Hi-Doctor25 €/mês (cobrado 25 € a cada 28 dias)
EM 60 SEGUNDOS
Victoza num relance
- A GLP-1 receptor agonist given as an injection under the skin once a day.
- Adults with a BMI of 30 or more, or 27 or more plus a weight-related illness.
- One injection every day, at any time, built up from 0.6 mg to 3.0 mg.
- Nausea and diarrhoea are very common; severe stomach pain can signal pancreatitis.
- Hi-Doctor consultation fee; the medicine is paid separately at a pharmacy
DADOS DA MARCA
Victoza num relance
- TITULAR DA AUTORIZAÇÃO DE INTRODUÇÃO NO MERCADO
- Novo Nordisk A/S
- APRESENTAÇÕES
- 6 mg/ml solution for injection in a pre-filled pen, delivering doses of 0.6 mg, 1.2 mg or 1.8 mg
Sobre o tratamento
O que é Victoza?
Victoza contém a substância ativa liraglutide.
Substância ativa: Liraglutide · Dosagens: 0.6 – 3 mg / day
Liraglutide is a GLP-1 receptor agonist given as a daily subcutaneous injection. It was one of the first in its class approved in Europe for weight management in adults with obesity, or overweight with comorbidities.
Compared with weekly GLP-1s, its daily dosing can be useful when flexibility of adjustment matters or when a semaglutide hasn't been tolerated. The doctor weighs this up in your consultation — two GLP-1 agonists are never combined.
COMO ATUA
O que Victoza faz no seu corpo
Like other GLP-1 analogues, liraglutide mimics a natural gut hormone: it eases hunger signals and produces earlier fullness, so you tend to eat less. Being shorter-acting, its dose is adjusted day by day.
Copies one gut hormone
Liraglutide is a copy of a natural gut hormone called GLP-1, which the body releases after eating. The EU product information describes it as an acylated human GLP-1 analogue with 97% amino acid sequence homology to the human hormone, and it binds to and activates the GLP-1 receptor.
Raises fullness, lowers hunger
GLP-1 receptors also sit in brain regions that regulate appetite. The product information reports that liraglutide increases feelings of fullness and satiety while lowering hunger and prospective food consumption, so people eat less. It does not increase energy expenditure compared with placebo.
Short-acting, so taken daily
Liraglutide has an elimination half-life of roughly 13 hours, which is why it is injected once every day rather than once a week like semaglutide or tirzepatide. It also raises insulin and lowers glucagon in a glucose-dependent way, and weight is lost mainly as fat mass.
Como ajuda
Three ways it supports weight loss.
Eases appetite
Earlier fullness and calmer hunger signals through the day.
Flexible dosing
Daily titration lets the doctor fine-tune the dose to your tolerance.
Long EU history
Among the first weight-management GLP-1s approved in Europe.
O que esperar
A gradual, week-by-week build-up.
Treatment starts at a low daily dose and steps up through the intermediate doses as tolerated. Your doctor sets the pace and adjusts if side effects appear.
- Week 1 · 0.6 mg daily starting dose
- Following weeks · Step up through 1.2, 1.8 and 2.4 mg as tolerated
- Maintenance · 3 mg daily when appropriate
- Ongoing · Follow-up through your account chat
Typical escalation
- Starting dose0.6 mg / day
- Step-ups1.2 → 1.8 → 2.4 mg / day
- Maintenance3 mg / day
O seu esquema é pessoal
Estes passos são apenas indicativos. O seu médico ajusta o plano à sua resposta e tolerância — e pode enviar-lhe uma mensagem em qualquer momento.
NO DIA A DIA
Usar Victoza no dia a dia
Inject once every day
Liraglutide is injected once daily, at any time of day, with or without food. Unlike weekly injections it needs a dose every 24 hours, so it is easiest to pick a convenient time and keep to it.
Start low and build up
Treatment starts at 0.6 mg once daily and rises by 0.6 mg at intervals of at least a week, reaching the 3.0 mg maintenance dose in week 5. The slow climb is there to improve stomach and bowel tolerance.
Tummy, thigh or upper arm
The injection goes under the skin of the abdomen, the thigh or the upper arm. It must never be given into a vein or a muscle. Rotate the site each day to reduce the risk of amyloid deposits building up under the skin.
Check the pen before use
Look at the liquid before you inject. It should be clear and colourless, or almost colourless. With a new pen, do the flow check described in the instructions so you can see a drop appear at the needle tip before setting your dose.
Missed dose: the 12 hour rule
If you remember within 12 hours of your usual time, take the dose as soon as you can. If there is less than 12 hours until the next one, skip it and carry on as normal. Never take an extra dose.
Store pens in the fridge
Unused pens are kept in a refrigerator between 2 and 8 degrees Celsius, away from the freezer compartment, and must not be frozen. A pen in use can be stored below 30 degrees Celsius or refrigerated, and is discarded one month after first use.
Drink enough fluid
Nausea, vomiting and diarrhoea are common at the start and can leave you short of fluid. Dehydration has been linked to kidney impairment and acute kidney failure on GLP-1 medicines, so drink plenty and tell your doctor if you cannot keep fluids down.
Keep the diet and activity going
Liraglutide is licensed as an addition to a reduced-calorie diet and increased physical activity, not as a replacement for them. Every trial result quoted on this page comes from people doing both alongside the daily injection.
Segurança primeiro
A segurança, por inteiro.
Victoza é um medicamento eficaz — e, como qualquer medicamento, acarreta riscos. O seu médico verifica tudo isto antes de prescrever. Este é o retrato honesto, não apenas palavras tranquilizadoras.
Efeitos secundários, por frequência
Stop and get urgent medical help if
seek medical help immediately
these need urgent attention, whatever the frequency
- Severe and lasting pain in the stomach area that may reach through to your back, which can signal pancreatitis
- Severe pain high in the tummy, usually worst on the right side under the ribs, which can signal gallstones or an inflamed gall bladder
- Breathing problems, or swelling of the face, lips, tongue or throat, which can signal a severe allergic reaction
- Vomiting or diarrhoea so severe or so lasting that you cannot keep fluids down, because dehydration can lead to kidney failure
- Cold sweat, pale skin, shakiness, headache and confusion, if you also take insulin or a sulfonylurea for diabetes
- A racing or pounding heartbeat while you are resting, which the prescriber needs to review
- Severe stomach pain with bloating and no bowel movement, which can signal a blocked bowel
Very common
very common (≥1/10)
more than 1 in 10 people
- Feeling sick (nausea), most often while the dose is being increased
- Being sick (vomiting)
- Diarrhoea
- Constipation
- Headache
Common
common (≥1/100 to <1/10)
between 1 in 100 and 1 in 10 people
- Low blood sugar symptoms, self-reported and not confirmed by a blood glucose reading, in people without type 2 diabetes
- Trouble sleeping, mainly during the first three months
- Dizziness
- A change in the sense of taste
- Dry mouth
- Indigestion, gastritis or acid reflux
- Pain in the upper part of the tummy
- Wind, burping or a bloated tummy
- Gallstones
- Rash
- Injection site reactions
- Weakness or tiredness
- Raised lipase or amylase on blood tests
Uncommon
uncommon (≥1/1,000 to <1/100)
between 1 in 1,000 and 1 in 100 people
- Dehydration
- A faster heart rate (tachycardia)
- Pancreatitis, which is inflammation of the pancreas
- Delayed stomach emptying
- Inflammation of the gall bladder (cholecystitis)
- Nettle rash (urticaria)
- Generally feeling unwell
Rare
rare (≥1/10,000 to <1/1,000)
between 1 in 10,000 and 1 in 1,000 people
- Anaphylactic reaction, a sudden and severe whole-body allergic reaction
- Acute kidney failure
- Kidney impairment
Frequency not known
frequency not known (cannot be estimated from the available data)
reported, but nobody can yet say how often it happens
- Intestinal obstruction, a blockage of the bowel, reported after the medicine went on the market
- Cutaneous amyloidosis, a lumpy deposit that can build up under the skin at the injection site
Adultos com obesidade (IMC ≥30) ou excesso de peso (IMC ≥27) com pelo menos uma condição associada como diabetes tipo 2, hipertensão ou dislipidemia.
- Autoinjeção diária na coxa, no abdómen ou no braço, a qualquer hora mas idealmente sempre à mesma.
- A dose é aumentada semana a semana até à dose de manutenção, para limitar o desconforto digestivo.
- Funciona em conjunto com dieta e atividade física — não substitui as mudanças de estilo de vida.
QUEM NÃO DEVE TOMAR E QUEM PRECISA DE PRECAUÇÃO
- You have ever had an allergic reaction to liraglutide or to any other ingredient in the pen. This is the only absolute contraindication in the EU product information.
- You are pregnant, or you want to become pregnant. Liraglutide should not be used in pregnancy, and treatment is discontinued if pregnancy occurs.
- You are breastfeeding. It is not known whether liraglutide passes into human milk, so it should not be used while breastfeeding.
- You or a close relative have had medullary thyroid carcinoma, or you have multiple endocrine neoplasia syndrome type 2. US labelling makes this an outright contraindication; EU labelling advises caution in anyone with thyroid disease.
- You have had pancreatitis. If pancreatitis is suspected liraglutide is stopped, and if it is confirmed it is not restarted.
- You have gallstones or gall bladder disease. Weight-management trials found more gallstones and gall bladder inflammation on liraglutide than on placebo.
- You have severe kidney impairment, including end-stage kidney disease, or severe liver impairment. Liraglutide is not recommended in these groups.
- You have inflammatory bowel disease or diabetic gastroparesis. Experience is limited and the medicine is not recommended, because it causes stomach and bowel effects.
- You already take another GLP-1 receptor agonist, or you would be using it as a replacement for insulin. Neither is allowed.
- You have New York Heart Association class IV heart failure, or you are 75 years or older. There is no clinical experience in these groups, so use is not recommended.
Quando procurar cuidados urgentes
Perante sintomas graves, súbitos ou inesperados, ligue para o número de emergência local ou dirija-se às urgências mais próximas. Depois, informe o seu médico através do chat da sua conta.
Medicamentos e substâncias que interagem
| MEDICAMENTO OU SUBSTÂNCIA | O QUE PODE ACONTECER | O QUE FAZ O MÉDICO |
|---|---|---|
| Insulin and sulfonylureas (for example gliclazide) | Combined use in type 2 diabetes raises the risk of low blood sugar, sometimes severe. | The prescriber may lower the insulin or sulfonylurea dose and asks for blood glucose self-monitoring. |
| Other GLP-1 receptor agonists | Two medicines acting on the same receptor add side effects without an established extra benefit. | Liraglutide for weight management must not be combined with another GLP-1 receptor agonist. |
| Warfarin and other coumarin blood thinners | No interaction study was done, and a clinically relevant effect on warfarin cannot be excluded. | The prescriber arranges more frequent INR checks when liraglutide is started. |
| Oral medicines in general | Liraglutide slightly delays stomach emptying, which can slow how fast a tablet is absorbed. | Interaction studies showed no clinically relevant delay, so no dose change is required. |
| Paracetamol | Peak paracetamol level fell by 31% and was reached up to 15 minutes later; total exposure was unchanged. | No dose adjustment is needed for paracetamol taken alongside liraglutide. |
| Combined oral contraceptives | Peak ethinylestradiol and levonorgestrel levels fell by 12% and 13%, with no relevant change in total exposure. | The contraceptive effect is expected to be unaffected, so no change is required. |
| Atorvastatin, digoxin and lisinopril | Peak levels fell by 38%, 31% and 27% respectively, with only small changes in total exposure. | No dose adjustment of any of these three is required based on those results. |
| General anaesthesia or deep sedation | Delayed stomach emptying can leave food in the stomach, and pulmonary aspiration has been reported. | Tell the anaesthetic team you take liraglutide before any procedure needing anaesthesia or sedation. |
Peça a um médico para analisar o seu casoÉ exatamente isto que o médico verifica antes de prescrever seja o que for.
Leia o resumo de segurança completo de VictozaEVIDÊNCIA
O que os ensaios clínicos encontraram
The SCALE phase 3 programme tested liraglutide 3.0 mg once daily against placebo in 5,358 adults, and reported a mean body-weight change of -8.0% at 56 weeks compared with -2.6% on placebo.
3,731 adults with BMI >= 30, or >= 27 with dyslipidaemia or hypertension · 56 weeks
SCALE Obesity and Prediabetes. Placebo changed -2.6%. In kilograms the change was -8.4 kg versus -2.8 kg from a mean baseline of 106.3 kg.
Fonte: Saxenda 6 mg/mL solution for injection in pre-filled pen: Annex I Summary of Product Characteristics3,731 adults without type 2 diabetes · 56 weeks
In the same trial 26.6% of the placebo group reached 5%. For a loss of more than 10% the figures were 32.8% and 10.1%.
Fonte: Saxenda 6 mg/mL solution for injection in pre-filled pen: Annex I Summary of Product Characteristics2,254 adults with prediabetes at screening · 160 weeks
Placebo changed -1.8%. The weight loss occurred mainly in the first year and was sustained through week 160.
Fonte: Saxenda 6 mg/mL solution for injection in pre-filled pen: Annex I Summary of Product Characteristics2,254 adults with prediabetes and obesity or overweight · 160 weeks
Estimated time to onset of type 2 diabetes was 2.7 times longer on liraglutide, with a hazard ratio of 0.2 versus placebo.
Fonte: Saxenda 6 mg/mL solution for injection in pre-filled pen: Annex I Summary of Product Characteristics422 adults who had already lost at least 5% on a low-calorie diet · 56 weeks
SCALE Maintenance. Placebo changed -0.2%. 81.4% on liraglutide kept at least 5% of the run-in loss, versus 48.9% on placebo.
Fonte: SCALE Maintenance: weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight lossThese figures are group averages from randomised trials, not a prediction for any one person. Some participants lost far more than the average and some lost very little, and everyone in these trials was also following an energy-restricted diet with exercise counselling alongside the daily injection. The product information also notes that of the people who had lost less than 5% after 12 weeks on the full dose, 93.4% did not go on to reach a 10% loss at one year, which is why the prescriber reviews progress at that point.
ALTERNATIVAS
Liraglutide vs other EU weight-management medicines
| MEDICAMENTO | COMO SE ADMINISTRA | COM QUE FREQUÊNCIA | INTERVALO DE DOSE HABITUAL | INDICAÇÃO AUTORIZADA NA UE | EVIDÊNCIA PRINCIPAL |
|---|---|---|---|---|---|
| Semaglutide | Injeção semanal | Uma vez por semana | 0.25–2.4 mg | Adjunct to a reduced-calorie diet and increased physical activity for weight management in adults with BMI ≥30, or ≥27 to <30 with at least one weight-related comorbidity. | STEP 1: mean -14.9% body weight at 68 weeks versus -2.4% placebo |
| Tirzepatide | Injeção semanal | Uma vez por semana | 2.5–15 mg | Adjunct to a reduced-calorie diet and increased physical activity for weight management in adults with BMI ≥30, or ≥27 to <30 with at least one weight-related comorbidity. | SURMOUNT-1: mean -20.9% body weight at 72 weeks versus -3.1% placebo |
| Orlistat | Cápsula oral | Com cada refeição principal | 120 mg per main meal | In conjunction with a mildly hypocaloric diet, for obese patients with BMI ≥30, or overweight patients with BMI ≥28 and associated risk factors. | XENDOS: mean 5.8 kg lost at four years versus 3.0 kg on placebo |
Não sabe qual se adequa ao seu caso? O médico analisa o seu historial e diz-lhe.
Iniciar consulta · 25 €/mêsACESSO E CUSTO
Como obter Victoza e quanto custa
Liraglutide is a centrally authorised medicine that is subject to medical prescription across the European Union, so no pharmacy can supply it without a valid prescription from a doctor. Who pays varies a lot by country: most national health systems do not cover it for weight management, so the patient pays the pharmacy directly. The entries for Spain, Germany, the Netherlands, Portugal, Ireland and Poland come from the national sources listed below; the rows for France, Italy, Belgium and Austria record the general position for this indication and are not confirmed against a national decision. The national database linked on each row is the authority on the current position.
O que paga à Hi-Doctor
25 €/mês (cobrado 25 € a cada 28 dias)
Responda a algumas perguntas e um médico licenciado na UE analisa o seu caso em menos de 2 horas, em média. Reembolso total se não for adequado para si.
O que a farmácia cobra
A Hi-Doctor não vende, não armazena nem dispensa medicamentos e não define o seu preço. O medicamento é pago à parte na farmácia e o valor depende do país, da embalagem, da existência de genérico e da comparticipação. A base de dados oficial ligada na tabela publica o preço autorizado em vigor.
| PAÍS | REGIME DE DISPENSA | COMPARTICIPADO PELO SISTEMA DE SAÚDE? | FONTE OFICIAL |
|---|---|---|---|
| Espanha | Medicamento sujeito a receita médica | Not reimbursed for weight management | AEMPS CIMA |
Ver os outros países
| Alemanha | Medicamento sujeito a receita médica | Excluded from statutory health insurance as a weight-regulation medicine | PharmNet.Bund AMIce |
|---|---|---|---|
| França | Medicamento sujeito a receita médica | Not reimbursed for weight management | Base de données publique des médicaments |
| Itália | Medicamento sujeito a receita médica | Not reimbursed for weight management | AIFA Medicinali |
| Países Baixos | Medicamento sujeito a receita médica | Restricted, conditions set in Regeling zorgverzekering bijlage 2 | CBG-MEB Geneesmiddeleninformatiebank |
| Portugal | Medicamento sujeito a receita médica | Not reimbursed for weight management | INFARMED Infomed |
| Bélgica | Medicamento sujeito a receita médica | Not reimbursed for weight management | FAGG-AFMPS medicines database |
| Irlanda | Medicamento sujeito a receita médica | Reimbursed by the HSE since January 2023, see national criteria | HPRA Find a Medicine |
| Áustria | Medicamento sujeito a receita médica | Not reimbursed for weight management | BASG Medikamente Info Austria |
| Polónia | Medicamento sujeito a receita médica | Not reimbursed, patient pays in full | Rejestr Produktów Leczniczych |
PREÇOS
Só paga se o tratamento for aprovado.
25 €/mês para perda de peso ou 15 €/mês (cobrado 45 € a cada 90 dias) para crescimento capilar. Para saúde sexual está disponível uma consulta pontual de 35 €.
Perda de peso
PLANO CONTÍNUO
25 €/mês
Cobrado 25 € a cada 28 dias · cancele a qualquer momento
Ciclo de tratamento de 28 dias
Para tratamento contínuo e renovações revistas pelo seu médico.
Renovações revistas pelo seu médico
Iniciar consulta
Reembolso total se uma avaliação não for aprovada
O QUE ESTÁ INCLUÍDO
- Primeira consulta incluída
- Renovações revistas pelo seu médico
- Cuidados contínuos com o seu médico
- Cancele a qualquer momento
Reembolso total se uma avaliação não for aprovada
Se uma avaliação não for aprovada, devolvemos a taxa de 25 € desse período e cancelamos o plano.
Nota: A medicação, se o médico a prescrever, é paga separadamente na farmácia ao preço que esta definir. A Hi-Doctor não vende medicamentos.
COMO DECIDE O MÉDICO
Um médico inscrito na Ordem analisa o seu caso, não um algoritmo
Um médico habilitado na UE lê o seu questionário e responde em menos de 2 horas, em média.
Se o médico decidir que não é seguro prescrever, o valor da consulta é reembolsado na íntegra.
O acompanhamento decorre no chat privado da sua conta, em conformidade com o RGPD. Sem WhatsApp, sem SMS.
PERGUNTAS FREQUENTES
Perguntas sobre Victoza.
OUTROS TRATAMENTOS DE PERDA DE PESO
Explore tratamentos relacionados.
FONTES
De onde vem esta informação
- 01
Saxenda (liraglutide): European public assessment report, medicine overview — European Medicines Agency, 2015
- 02
Saxenda 6 mg/mL solution for injection in pre-filled pen: Annex I Summary of Product Characteristics — European Medicines Agency, 2026
- 03
Saxenda 6 mg/mL solution for injection in pre-filled pen: Summary of Product Characteristics — electronic medicines compendium (emc), 2026
- 04
Saxenda 6 mg/mL solution for injection in pre-filled pen: Patient Information Leaflet — electronic medicines compendium (emc), 2026
- 05
Liraglutide (Saxenda, Diavic, Zegluxen): NHS medicines A to Z — NHS, 2026
- 06
SCALE Obesity and Prediabetes: a randomized, controlled trial of 3.0 mg of liraglutide in weight management — New England Journal of Medicine, 2015
- 07
SCALE Maintenance: weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss — International Journal of Obesity, 2013
- 08
Victoza (liraglutide): European public assessment report, medicine overview — European Medicines Agency, 2009
- 09
Saxenda (liraglutide) injection: US prescribing information, boxed warning and contraindications — DailyMed, US National Library of Medicine, 2026
- 10
CIMA: Saxenda presentations, marketing and prescription status in Spain — AEMPS (Spanish Agency of Medicines and Medical Devices), 2026
- 11
Sozialgesetzbuch V § 34: medicines excluded from statutory health insurance, including those for weight regulation — Bundesministerium der Justiz (gesetze-im-internet.de), 2026
- 12
Liraglutide: preparaattekst and vergoeding conditions in the Netherlands — Farmacotherapeutisch Kompas, Zorginstituut Nederland, 2026
- 13
Liraglutide (Saxenda): health technology assessment and HSE reimbursement decision — National Centre for Pharmacoeconomics (Ireland), 2023
- 14
Rejestr Produktow Leczniczych: Saxenda registration record in Poland — Centrum e-Zdrowia (Poland), 2026
- 15
INFOMED: base de dados de medicamentos de uso humano — INFARMED (Portugal), 2026
- 16
STEP 1: Once-weekly semaglutide in adults with overweight or obesity — New England Journal of Medicine, 2021
- 17
SURMOUNT-1: Tirzepatide once weekly for the treatment of obesity — New England Journal of Medicine, 2022
- 18
XENDOS: XENical in the prevention of Diabetes in Obese Subjects, a 4-year randomised study — Diabetes Care, 2004
- 19
Wegovy (semaglutide) solution for injection: Summary of Product Characteristics — electronic medicines compendium (emc), 2026
- 20
Xenical 120 mg hard capsules: Summary of Product Characteristics — electronic medicines compendium (emc), 2026
Revisto pela equipa médica da Hi-Doctor · Última revisão 2026-07-27 · Próxima revisão prevista em 2027-07-27
Esta página contém informação sobre um medicamento; não é uma recomendação para o tomar nem substitui uma consulta médica. Só um médico habilitado que tenha analisado o seu historial pode decidir se um tratamento é adequado para si.
Descubra se é adequado para si
Veja se Victoza é apropriado para si.
Responda a algumas perguntas e um médico licenciado na UE analisa o seu caso em menos de 2 horas, em média. Reembolso total se não for adequado para si.